XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.15

+2.8%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: opalapril who wrote (8409)	1/21/1999 8:48:00 PM
From: William L. Molair II	Read Replies (2) of 17367

I debated about posting the following info earlier (I didn't clearly understand Ellen's comments). So, beware of the following's accuracy. The Phase III trial was designed based upon an endpoint of total number of deaths - because the disease is pretty rare and they did not think that they could get a large enough participants to be statistically significant. This was agreed to by the FDA. OK I said it. I do not understand it; but it made a lot of sense to Ellen. Again, I was not real clear on this part of our conversation, and it may be inaccurate. So call Ellen.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next